The BCMA-targeted therapies have been undergoing extensive development in MM, including antibody drug conjugates, bispecific antibodies, and CAR T cell therapies, all achieved remarkable clinical outcomes [8, 24, 25]. Here, TNFRSF17 is linked to Miyoshi myopathy.